Teleflex Incorporated (NYSE:TFX) Director Stuart A. Randle sold 4,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $290.52, for a total transaction of $1,162,080.00. Following the transaction, the director now owns 7,421 shares of the company’s stock, valued at $2,155,948.92. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Teleflex stock opened at $298.86 on Friday. Teleflex Incorporated has a 12-month low of $226.02 and a 12-month high of $301.93. The stock has a market cap of $13.64 billion, a price-to-earnings ratio of 30.19, a PEG ratio of 1.99 and a beta of 1.06. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.39 and a current ratio of 2.12.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, February 21st. The medical technology company reported $2.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.76 by $0.01. Teleflex had a net margin of 8.20% and a return on equity of 18.47%. The company had revenue of $641.60 million for the quarter, compared to analysts’ expectations of $641.06 million. During the same period last year, the company earned $2.44 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities research analysts expect that Teleflex Incorporated will post 11.02 EPS for the current fiscal year.
Several research firms have weighed in on TFX. Barclays set a $287.00 target price on shares of Teleflex and gave the company a “hold” rating in a report on Friday, February 22nd. TheStreet raised shares of Teleflex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 28th. Zacks Investment Research raised shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Tuesday, February 26th. Morgan Stanley raised their price target on shares of Teleflex from $305.00 to $315.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and set a $325.00 price target (up from $300.00) on shares of Teleflex in a research note on Friday, February 22nd. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $297.00.
Institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC boosted its position in shares of Teleflex by 21.1% in the third quarter. Private Advisor Group LLC now owns 2,848 shares of the medical technology company’s stock worth $758,000 after acquiring an additional 496 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Teleflex during the third quarter valued at approximately $260,000. Virginia Retirement Systems ET AL lifted its position in Teleflex by 21.7% during the third quarter. Virginia Retirement Systems ET AL now owns 2,800 shares of the medical technology company’s stock valued at $745,000 after buying an additional 500 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in Teleflex by 2.0% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 24,985 shares of the medical technology company’s stock valued at $6,648,000 after buying an additional 500 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in Teleflex by 12.1% during the third quarter. Janney Montgomery Scott LLC now owns 9,202 shares of the medical technology company’s stock valued at $2,449,000 after buying an additional 994 shares in the last quarter. 91.17% of the stock is currently owned by institutional investors.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.